SB3772 amends three provisions of the Export‑Import Bank Act of 1945 to replace near‑term sunset dates with dates a decade later. It replaces the Bank’s general authorization date and a China/transformational export program date with 2036, and moves the statute’s aggregate loan, guarantee, and insurance authority date to 2037.
The bill is purely temporal: it keeps Ex‑Im’s statutory authorities active for another ten years without changing program design, eligibility, oversight, or reporting requirements. For exporters, lenders, and foreign buyers that rely on Ex‑Im financing, the bill preserves continuity; for policymakers and budget officers it extends contingent federal exposure without accompanying reforms.
At a Glance
What It Does
SB3772 updates three statutory expiration dates in the Export‑Import Bank Act: Section 7 (general authorization) and the China/transformational exports provision move to 2036, and the aggregate loan/guarantee/insurance authority in Section 6(a)(2) moves to 2037. The bill performs no other substantive changes to program rules or governance.
Who It Affects
The primary operational impact is on the Export‑Import Bank itself and the businesses—especially capital‑intensive exporters and their lenders—that use its loans, guarantees, and insurance. It also affects federal budget officials who track contingent liabilities and any parties that rely on Ex‑Im continuity for multi‑year transactions.
Why It Matters
By extending authorization dates the bill prevents a statutory lapse that could interrupt existing or planned financing. It preserves U.S. export competitiveness in markets where state-backed finance is common, while simultaneously extending federal contingent exposure without altering risk controls or reporting requirements.
More articles like this one.
A weekly email with all the latest developments on this topic.
What This Bill Actually Does
SB3772 is a short, technical bill that does one thing: it replaces three calendar years in the Export‑Import Bank Act of 1945 with later dates. The text amends the statute itself rather than creating new authorities or rider programs.
Because the bill only swaps dates, it does not change who qualifies for Ex‑Im support, how transactions are structured, or the Bank’s oversight framework.
The statutory edits target three distinct places in the statute. One edit lengthens the Bank’s basic authorization window so the agency can continue to operate under its existing charter through 2036.
A second edit lengthens the special statutory language that governs the Bank’s program addressing China and transformational exports through 2036. A third edit extends the cap on the Bank’s aggregate outstanding exposure—its loan, guarantee, and insurance authority—through 2037.
That last change is notable because it leaves the exposure cap effective one year longer than the Bank’s general authorization.Because SB3772 does not alter eligibility, pricing, or risk‑management provisions, existing underwriting, approval, and documentation practices remain in place. The practical effect, if enacted, is to remove near‑term legal uncertainty for ongoing transactions and give Ex‑Im and its customers a predictable legal horizon for new long‑term deals.
It does not create new budget authority; instead it pushes forward the dates at which those statutory permissions expire, which in turn preserves the Bank’s ability to make new commitments and keep existing ones in force under current law.Finally, the bill’s narrow scope means it does not address broader policy debates about Ex‑Im’s mission, transparency, or risk controls. Entities that wanted substantive reform—changes to exposure limits, reporting, underwriting standards, or program priorities—will not find them in this text.
That makes SB3772 an administrative continuity bill rather than a policy overhaul.
The Five Things You Need to Know
The bill amends Section 7 of the Export‑Import Bank Act of 1945 by replacing the year “2026” with “2036,” extending the Bank’s basic statutory authorization for ten years.
It amends Section 6(a)(2) (the statute’s aggregate loan, guarantee, and insurance authority) by changing the expiration year from “2027” to “2037,” creating a one‑year difference between the Bank’s authorization and its aggregate exposure authority.
SB3772 amends Section 2(l)(3)(C)—the statute’s provision that addresses the program for China and transformational exports—by replacing each occurrence of “2026” with “2036.”, The bill contains only date amendments; it makes no changes to eligibility, underwriting standards, reporting, oversight structures, or new funding mechanisms in the underlying statute.
Senator Kevin Cramer introduced the bill (with Senator Mark Warner listed as a cosponsor in the text) on February 4, 2026; the text reads as a technical reauthorization rather than a policy reform package.
Section-by-Section Breakdown
Every bill we cover gets an analysis of its key sections.
Short title
This section names the measure the 'Export‑Import Bank Reauthorization Act of 2026.' That entry is purely formal; it does not change substance but provides the bill’s public title for use in reports and citations.
Extend Ex‑Im’s general authorization to 2036
This subsection edits Section 7 of the Export‑Import Bank Act of 1945 by striking the expiration year “2026” and inserting “2036.” Section 7 is the statutory provision that sets the outer date for the Bank's authority to operate. Mechanically, this gives Ex‑Im an additional ten years of statutory life under current law and prevents a statutory termination at the earlier date that could otherwise have forced the Bank to stop making new commitments or wind down.
Pushes aggregate exposure authority to 2037
This subsection amends the statute that governs the Bank’s aggregate loan, guarantee, and insurance authority by replacing “2027” with “2037.” That provision caps the period during which Ex‑Im may incur new aggregate exposure. Practically, the amendment allows the Bank to retain authority to carry aggregate commitments through 2037—one year beyond the general authorization extension—so administrators and counsel will need to account for the staggered expiration dates when planning multi‑year financing and wind‑down scenarios.
Extends the China and transformational exports program authority to 2036
This subsection replaces each occurrence of “2026” in the statute’s provision addressing the Bank’s program for China and transformational exports with “2036.” That program is a targeted statutory framework within the Act; the change keeps that targeted authority in force alongside the Bank’s broader authorization, preserving the Bank’s ability to prioritize or designate transactions under that caption as currently written.
This bill is one of many.
Codify tracks hundreds of bills on Finance across all five countries.
Explore Finance in Codify Search →Who Benefits and Who Bears the Cost
Every bill creates winners and losers. Here's who stands to gain and who bears the cost.
Who Benefits
- U.S. exporters of long‑term, capital‑intensive goods (e.g., aerospace, heavy machinery): The extension preserves access to Ex‑Im financing and guarantees used to close multi‑year sales that private capital markets may not fully support.
- Small and medium‑sized exporters that depend on Ex‑Im credit insurance and working capital guarantees: Continuity reduces the risk that programs they rely on will lapse during active transactions or when seeking new foreign buyers.
- Private lenders and commercial insurers that partner with Ex‑Im: Lenders retain the option to use Ex‑Im guarantees to mitigate credit risk on cross‑border transactions, sustaining deal flow that depends on public backing.
- Foreign purchasers and project sponsors that require export credit support: Buyers who require competitive financing terms from state‑backed sources keep a predictable financing pathway, which matters in markets dominated by other export credit agencies.
Who Bears the Cost
- U.S. taxpayers (through contingent liabilities): Extending the Bank’s authority keeps potential federal exposure on the books; new commitments remain federally guaranteed until repaid or written off, which maintains contingent fiscal risk.
- Congressional budget and oversight offices: Agencies that track federal exposure and audit Ex‑Im will have to continue monitoring commitments for an extended period without any statutory improvement in transparency or reporting.
- The Bank’s risk managers and legal teams: The staggered expiration dates (2036 vs. 2037) create administrative complexity for structuring commitments that span the Bank’s authorization horizon.
- Opponents of Ex‑Im activity (e.g., competing policy priorities): Because the bill does not pair extension with reforms, parties seeking changes to mandate, transparency, or conditionality must pursue separate legislation.
Key Issues
The Core Tension
The bill resolves near‑term legal uncertainty for exporters by preserving Ex‑Im’s authority, but it does so without tackling the fiscal and governance questions that long‑term extension magnifies: continuity for trade competitiveness versus prolonged contingent taxpayer exposure and a missed opportunity to update risk controls and transparency.
SB3772 delivers legal continuity by changing expiration years, but that simplicity hides practical and policy trade‑offs. First, the bill extends contingent federal exposure without accompanying reforms to underwriting, transparency, or conditionality.
That means the fiscal footprint remains intact for a longer period while the statutory structure that produced that footprint stays unchanged.
Second, the bill creates a small but meaningful timing disconnect: the Bank’s general authorization is extended to 2036, while the aggregate exposure authority is extended to 2037. That stagger could complicate how the Bank structures long‑dated commitments, wind‑down plans, or multi‑year projects near the authorization horizon.
Agencies, counsel, and counterparties will need to reconcile the mismatch when planning transactions that begin before one date but have economic life beyond it.
Finally, because SB3772 is deliberately narrow, it forgoes an opportunity to address persistent implementation questions—how Ex‑Im measures and reports risk, how it coordinates with private finance, or how it prioritizes strategic sectors. Stakeholders who want reforms must seek separate measures; otherwise continuity comes at the price of delayed modernization.
Try it yourself.
Ask a question in plain English, or pick a topic below. Results in seconds.